Hangzhou Tigermed Consulting News

Tiger Pharmaceuticals (300347): Revenue improved month-on-month, new orders continued to improve

Kaiyuan SecuritiesNov 3 00:00

Tiger Pharmaceuticals (300347): Short-term multiple factors disrupt and are optimistic about the trend of improving performance

cscNov 1 18:12

Tiger Pharmaceuticals (300347) 2024 three-quarter report review: gross margin is under pressure, waiting for the industry to pick up

everbrightNov 1 00:00

CICC: Maintains tigermed (03347) 'outperform' rating, target price cut to 48.6 Hong Kong dollars.

Zhitong FinanceOct 30 16:05

Credit rating by major banks | Lyon: Lowering Tigermed's target price to HKD 48.6, lowering earnings forecast per share from 2024 to 2026.

Gelonghui FinanceOct 30 14:54

Tiger Pharmaceuticals (300347): Q2 performance improved month-on-month, and new orders recovered steadily

Guosheng SecuritiesSep 21 00:00

Tiger Pharmaceuticals (300347): Q2 performance improved month-on-month, and overall steady growth in new orders

Aug 31 14:36

TIGERMED(300347):ORDER GROWTH IN 1H24 SIGNALS REDUCED UNCERTAINTIES IN DEMAND RECOVERY

Aug 30 15:07

Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$28.56 From HK$30.65, Keeps at Neutral

MT NewswiresAug 29 17:38

Tiger Pharmaceuticals (300347) innovative drug environment response to performance side improving quality and efficiency to stabilize gross margin

Aug 29 16:36

Tiger Pharmaceuticals (300347): Orders have achieved rapid growth and are expected to continue the month-on-month recovery trend

Aug 29 13:16

Tiger Pharmaceuticals (300347): Innovative policies catalyze steady growth of integrated clinical CRO leaders

Jul 25 19:22

Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$30.65 From HK$32.69, Keeps at Neutral

MT NewswiresJul 24 17:35

Tiger Pharmaceuticals (300347): Hengqiang, the leading clinical CRO leader

Jun 2 00:00

Tiger Pharmaceuticals (300347) In-depth Research Report: Local clinical CRO leaders are expected to fully benefit from the industry's rise in volume and price

May 12 00:00

TIGERMED(300347):MEANINGFUL DEMAND RECOVERY IN 1Q24

招银国际Apr 29 14:11

Tiger Pharmaceuticals (300347) Company Information Update Report: Performance is under phased pressure and is expected to gradually recover in 2024

Apr 29 00:00

Tiger Pharmaceuticals (300347): Short-term demand under pressure is expected to improve to drive a recovery in performance

Apr 28 13:51

Tiger Pharmaceuticals (300347): Multiple factors disrupt Q1 and expect innovative drug policies to boost the gradual recovery of the industry

Apr 28 00:00

Tiger Pharmaceuticals (300347): Business performance is basically in line with expectations, and innovation support policies are expected to reverse

Apr 26 15:36